Spectrum appoints Amgen vet Ken Keller as COO

Thursday, September 13, 2012 08:00 AM

Spectrum Pharmaceuticals, a biotechnology company focused on hematology and oncology, has appointed Ken Keller as executive vice president and COO. Keller will have global responsibility for leading commercial operations, medical and clinical development and pharmaceutical operations.

He brings more than 20 years of experience in the pharmaceutical industry ranging from sales and marketing leadership, general management and joint venture leadership in several therapeutic areas, including oncology, rheumatology, dermatology and primary care. Prior to joining Spectrum, Keller spent 21 years at Amgen. His most recent role was vice president and general manager, bone health business unit, Amgen. During his career at Amgen, Keller has been the marketing lead or the general manager for four of the world's top selling biologic medicines Neupogen, Neulasta, Aranesp and Enbrel. He also has significant international experience, as managing director for Amgen's U.K. and Ireland affiliate.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs